News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Asim V. Farooq, MD, University of Chicago Medical Center

Articles by Asim V. Farooq, MD, University of Chicago Medical Center

Influencing Factors to Initially Targeting BCMA in MM

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 25th 2021

DREAMM-2 Trial Regimen Safety Profile

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 18th 2021

The Rationale for Targeting BCMA in Multiple Myeloma

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

December 18th 2020

Latest Updated Articles

Influencing Factors to Initially Targeting BCMA in MM
Published: February 1st 2021 | Updated:
Management of Ocular Events From DREAMM-2 Regimen
Published: January 25th 2021 | Updated:
The Rationale for Targeting BCMA in Multiple Myeloma
Published: December 18th 2020 | Updated:
Treatment Approach for R/R Multiple Myeloma
Published: December 18th 2020 | Updated:
DREAMM-2 Trial Regimen: Safety Updates and Dose Delay
Published: January 25th 2021 | Updated:
Next Steps for Use of Belantamab in Clinical Practice
Published: February 1st 2021 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma